NCT02223923 2025-08-01
Patriot
Royal Marsden NHS Foundation Trust
Phase 1 Unknown
Clinical Trials
8,842 trialsNCT02637479 2025-01-30
Hyporadoul
Assistance Publique Hopitaux De Marseille
Phase NA Unknown
NCT06216743 2024-12-31
PRE-MISTIC
Radboud University Medical Center
Phase NA Unknown
NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT06678230 2024-11-07
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Phase 2 Unknown
NCT06659406 2024-10-26
PCOS
University of Faisalabad
Phase NA Unknown
NCT02236910 2024-10-15
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Unknown
NCT06121752 2024-10-15
DNET
Asian Institute of Gastroenterology, India
Phase NA Unknown
NCT05644821 2024-10-01
PRO-P
Heinrich-Heine University, Duesseldorf
Phase NA Unknown
NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
NCT04354233 2024-08-21
ABLE02
Centre Leon Berard
Phase NA Unknown
NCT05452668 2024-08-21
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
Children's Cancer Hospital Egypt 57357
Phase NA Unknown
NCT03612232 2024-08-19
CaboACC
Wuerzburg University Hospital
Phase 2 Unknown
NCT06556004 2024-08-15
Trimelvax001
University of Chile
Phase 1 Unknown
NCT06157359 2024-08-09
Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT03362801 2024-07-19
SAMPHYR
University Hospital, Caen
Phase NA Unknown
NCT05183243 2024-07-16
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
Phase 1 Unknown
NCT04939883 2024-06-28
CardioTox
Hospital Sirio-Libanes
Phase 4 Unknown
NCT05240625 2024-06-20
Clinical Efficacy Evaluation of a Computer-aided Colonoscopy as Compared With the Standard Colonoscopy.
National Taiwan University Hospital
Phase NA Unknown
NCT05155618 2024-06-18
MicroStyle
European Institute of Oncology
Phase NA Unknown
NCT03818386 2024-06-14
NANORAD2
University Hospital, Grenoble
Phase 2 Unknown
NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT06455722 2024-06-12
[68Ga]Ga-P15-041 PET/CT in Variety of Bone Tumors
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT05638451 2024-06-05
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Phase 2 Unknown
NCT04547634 2024-06-04
Telerehabilitation in Oncology Patients
University of Malaga
Phase NA Unknown
NCT06136065 2024-06-04
FAPI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Unknown
NCT06435741 2024-05-30
Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT05075356 2024-05-14
iToBoS
The University of Queensland
Phase NA Unknown
NCT01516710 2024-05-10
Oslo-CoMet
Oslo University Hospital
Phase NA Unknown
NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06395337 2024-05-02
MIRCA & MIPAC
Radboud University Medical Center
Phase 1/2 Unknown
NCT04557020 2024-05-01
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
Jiangxi Provincial Cancer Hospital
Phase 3 Unknown
NCT06385665 2024-04-26
The Effect of Appropriate Family Companionship on the Physical and Mental Health of Patients With Advanced Breast Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Unknown
NCT06217250 2024-04-18
COWL
Istituto Clinico Humanitas
Phase NA Unknown
NCT05919212 2024-04-15
DIAMOND
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase NA Unknown
NCT03425565 2024-04-12
PEACOCC
University College, London
Phase 2 Unknown
NCT06150131 2024-04-12
Exercise Intervention After Lung Cancer Surgery
Region Örebro County
Phase NA Unknown
NCT06356701 2024-04-10
Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC
The First Affiliated Hospital of Dalian Medical University
Phase 1 Unknown
NCT05106244 2024-04-03
RRTGS
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06331962 2024-03-26
Digestive Tract Cancer and CIPN
National Cheng-Kung University Hospital
Phase NA Unknown
NCT06156020 2024-03-21
Outcome Analysis of Endoscopic Resection of Pituitary Adenomas
National Cheng-Kung University Hospital
Phase NA Unknown
NCT06322563 2024-03-21
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05143970 2024-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Unknown
NCT05649046 2024-03-18
PREVALUNG*
Assistance Publique Hopitaux De Marseille
Phase NA Unknown
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown